However, elevated RLN2 levels have been reported in other cancers, such as prostate cancer, breast cancer, and osteosarcoma, where they correlate with disease progression and poorer prognosis [37,38], which prompted us to conduct research on this parameter. This evidence concerns the gene RLN2 and prostate carcinoma.